Steve Scala
Stock Analyst at TD Cowen
(2.85)
# 1,750
Out of 4,947 analysts
31
Total ratings
73.08%
Success rate
13.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Scala
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Buy | $195 → $225 | $204.68 | +9.93% | 12 | Oct 7, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $59 | $47.81 | +23.41% | 3 | Oct 7, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $90 → $95 | $78.47 | +21.07% | 1 | Aug 12, 2024 | |
| MRK Merck & Co. | Upgrades: Outperform | $125 → $135 | $82.76 | +63.12% | 1 | Jan 4, 2024 | |
| PFE Pfizer | Downgrades: Market Perform | $32 | $25.11 | +27.44% | 1 | Jan 4, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $430 → $500 | $684.43 | -26.95% | 8 | May 23, 2023 | |
| NVS Novartis AG | Downgrades: Market Perform | $110 → $105 | $122.09 | -14.00% | 4 | Feb 1, 2021 | |
| RPRX Royalty Pharma | Initiates: Outperform | $55 | $36.50 | +50.68% | 1 | Jul 13, 2020 |
AbbVie
Oct 7, 2024
Maintains: Buy
Price Target: $195 → $225
Current: $204.68
Upside: +9.93%
Bristol-Myers Squibb Company
Oct 7, 2024
Maintains: Hold
Price Target: $53 → $59
Current: $47.81
Upside: +23.41%
AstraZeneca
Aug 12, 2024
Maintains: Buy
Price Target: $90 → $95
Current: $78.47
Upside: +21.07%
Merck & Co.
Jan 4, 2024
Upgrades: Outperform
Price Target: $125 → $135
Current: $82.76
Upside: +63.12%
Pfizer
Jan 4, 2024
Downgrades: Market Perform
Price Target: $32
Current: $25.11
Upside: +27.44%
Eli Lilly and Company
May 23, 2023
Maintains: Outperform
Price Target: $430 → $500
Current: $684.43
Upside: -26.95%
Novartis AG
Feb 1, 2021
Downgrades: Market Perform
Price Target: $110 → $105
Current: $122.09
Upside: -14.00%
Royalty Pharma
Jul 13, 2020
Initiates: Outperform
Price Target: $55
Current: $36.50
Upside: +50.68%